Trial Profile
Phase I study of azacitidine [Vidaza] in combination with cisplatin patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 02 Mar 2017
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Cisplatin
- Indications Head and neck cancer
- Focus Adverse reactions
- 25 Aug 2009 Celgene Corporation added as trial sponsor and lead trial centre as reported by ClinicalTrials.gov.
- 12 Jun 2008 Patient numbers amended from 24 to 1 as reported by ClinicalTrials.gov
- 12 Jun 2008 Status changed from recruting to discontinued as reported by ClinicalTrials.gov